Moreover, the authors compared their results to similar context-dependent effects observed in colon cancer models and concluded that the clinical efficacy of PPARγ agonists depends on the balance between their antitumor activity in epithelial cancer cells and their pro-tumor activity in immune cells within the tumor microenvironment [64,65]. The gene discussed is PPARG; the disease is neoplasm.